Showing 1061-1070 of 1634 results for "".
- Allergan to Buy Soliton and Resonic, Its Rapid Acoustic Pulse Devicehttps://modernaesthetics.com/news/allergan-to-buy-soliton/2473103/Allergan Aesthetics is set to acquire Soliton and Resonic, its Rapid Acoustic Pulse device. Resonic recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition o
- Dr. Deanne Mraz Robinson is Now CMO at Ideal Imagehttps://modernaesthetics.com/news/dr-deanne-mraz-robinson-is-now-cmo-at-ideal-image/2473099/Deanne Mraz Robinson, MD, FAAD has been appointed to serve as Chief Medical Officer for Ideal Image. She will be responsible for the overall direction of treatments and services offered by Ideal Image, the education of its clinical specialists, and he
- Dermatologists Report Uptick in Cosmetic Consults Due to Zoom Dysmorphiahttps://modernaesthetics.com/news/dermatologists-report-uptick-in-cosmetic-consults-due-to-zoom-dysmorphia/2473093/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified d
- With Nods from Shape, InStyle and More, BTL Devices Sweep Magazine Award Seasonhttps://modernaesthetics.com/news/btl-devices-sweep-magazine-awards-season/2473085/BTL Aesthetics’ took home five awards from several aesthetic publications for Emsculpt Classic, Emsculpt NEO, and Emsella. Emsculpt therapy was named the winner of the 2020 Aestheticians Choice Award for Favorite Body Sculpting Device in Dermascop
- It's A Deal: Eirion Therapeutics, Shanghai Haohai Biological Technology Close $40M Series A Investment and Licensing Dealhttps://modernaesthetics.com/news/its-a-deal-eirion-therapeutics-inc-shanghai-haohai-biological-technology-closes-40m-series-a-investment-and-licensing-deal/2473070/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- FDA Greenlights Galderma's Restylane Defyne for Chin Augmentationhttps://modernaesthetics.com/news/fda-greenlights-galdermas-restylane-defyne-for-chin-augmentation/2473055/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Pulse Biosciences Receives European Clearance for CellFX Systemhttps://modernaesthetics.com/news/pulse-biosciences-receives-european-clearance-for-cellfx-system/2473050/Pulse Biosciences, Inc. will proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU), now that it has received CE mark for the system. The European clearance is for the treatment of general dermatologic conditions, includi
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r